Vince Ippolito Net Worth: How to Estimate and Verify It

Based on publicly available ASX filings, Botanix Pharmaceuticals remuneration disclosures, and insider trading records, the most evidence-backed net worth estimate for Vince Ippolito (the pharmaceutical executive and Botanix Executive Chairman) falls in the range of approximately $5 million to $15 million USD as of mid-2026. That range reflects verified equity holdings in Botanix, disclosed annual compensation exceeding A$5.6 million in FY2025, and a 30-plus-year career in senior pharmaceutical roles, while acknowledging that private assets and investments outside of public filings remain unknown.

Which Vince Ippolito this search is actually about

The name returns at least two distinct professional profiles, and the confusion is worth sorting out before diving into numbers. If you are specifically tracking Danilo Iervolino net worth, make sure you are looking at the correct person, since this article focuses on Vince Ippolito. The first is a pharmaceutical and dermatology executive with a documented career spanning Novartis, Medicis (the company behind Restylane and Dysport), Valeant, and Anacor Pharmaceuticals. He joined Anacor as Executive Vice President and Chief Commercial Officer in March 2014, and in July 2019 was appointed President and Executive Chairman of Botanix Pharmaceuticals (ASX: BOT), an Australian-listed biotech company focused on cannabidiol-based treatments. His full legal name in ASX filings is Vincent Peter Ippolito, and he holds his shares through an entity called the Ippolito Trust. This is the identity all credible net worth research points to.

The second profile is a corporate project or program manager associated with Bristol-Myers Squibb and Rider University, located in Virginia Beach, Virginia. That person shares the name but has no known connection to biotech executive compensation, equity stakes, or public disclosures. If you specifically meant Ivan Soldo, verify whether the source is confusing him with Vince Ippolito, because many public profiles mix identities and can skew net worth claims Ivan Soldo net worth. If you landed on a net worth estimate tied to this second profile, it is almost certainly misattributed. For the purposes of this article, everything below refers to the pharmaceutical executive.

The estimated net worth range, explained

A single definitive number does not exist for Vince Ippolito because no complete public asset disclosure is required of him outside of his role as a listed company director. What does exist is enough verified data to build a reasonable range. MarketScreener maintains an insider profile for Vincent P. Ippolito with a net worth figure noted as of April 2026, but does not publish a transparent methodology behind it. Sites like PeopleAI produce estimates they explicitly describe as based on social factors rather than financial accounting, making them essentially unreliable for this purpose. The range below is built from primary sources.

The most defensible floor sits around $5 million USD. That reflects the minimum value that can be inferred from disclosed Botanix equity after his January 2025 share sale, modest assumptions about accumulated savings from a three-decade executive career, and the cash component of his compensation. The ceiling of around $15 million reflects a scenario where Botanix shares appreciate meaningfully before his remaining performance rights expire in December 2029, where prior career equity events (Anacor was acquired by Pfizer in 2016 for $5.2 billion, which likely generated some value for senior commercial leadership) contributed meaningfully, and where private investment or real estate holdings exist at a level typical for executives at his seniority. Beyond $15 million is possible but speculative without further disclosure.

How net worth estimates are built for executives like this

For publicly listed company executives, net worth research follows a fairly standard methodology even when full financial statements are not available. The process starts with what is provably disclosed, then layers in reasonable assumptions for what is not.

1. Identify all public filings that reveal compensation: remuneration tables in annual reports or prospectuses, director interest notices, and any proxy-equivalent disclosures. For Botanix, the prospectus remuneration table is the clearest source.
2. Calculate the cash component of annual compensation and estimate an accumulation period. Ippolito's FY2025 salary and fees came to A$694,838, with an additional A$356,839 categorized as 'other' compensation.
3. Value the equity component at current market price. The prospectus table shows equity incentives of A$4,596,497 for FY2025 alone, though much of this reflects accounting value of unvested rights rather than realized cash.
4. Review insider transaction filings for actual realized proceeds. The January 2025 ASX disclosure shows he exercised 8,000,000 performance rights (valued at $0.44 per share at exercise) and sold 3,800,000 shares, generating verifiable proceeds of approximately A$1.67 million from that sale alone.
5. Check remaining holdings and outstanding options or rights. His remaining performance rights package runs to December 2029, creating future value dependent on share price and vesting conditions.
6. Apply a discount for illiquidity, tax obligations, and the portion of equity accounting value that has not yet vested or been realized.
7. Acknowledge the private wealth gap: career history, prior exit events, and personal investment activity outside public markets are not captured in any of the above.

The income and asset categories driving his wealth

Understanding where the money likely comes from makes the estimate more credible than a single headline figure.

Current executive compensation at Botanix

Botanix increased Ippolito's base pay from US$400,000 to US$450,000 annually (as announced in October 2024), with additional incentives tied to revenue milestones and performance rights. The FY2025 total compensation in the prospectus remuneration table reached A$5,669,939, though the dominant portion of that figure is equity-based accounting value rather than cash in hand. His cash salary and fees of A$694,838 plus the A$356,839 'other' category represent the more immediate income floor.

Botanix equity holdings

The Ippolito Trust holds fully paid ordinary shares in Botanix following the January 2025 performance rights exercise. After exercising 8 million rights and selling 3.8 million shares, his remaining holding is substantial. Because Botanix is an ASX-listed micro-to-small-cap biotech, share price volatility means this component of net worth can shift considerably. Any realistic estimate needs to be updated against the current BOT share price rather than treated as a fixed number.

Prior career events, including the Pfizer-Anacor acquisition

Ippolito served as Chief Commercial Officer at Anacor Pharmaceuticals until September 2017. Anacor was acquired by Pfizer in June 2016 for approximately $5.2 billion. Senior commercial leadership at acquired biotech companies often hold stock options or RSUs that generate significant liquidity at deal close, though the exact value accruing to Ippolito from that event is not publicly documented. His tenure at Medicis (acquired by Valeant in 2012 for $2.6 billion) represents another potential prior exit event. These are plausible but unconfirmed contributors to private wealth.

Private assets outside public filings

Real estate, personal investment accounts, retirement savings, and other private holdings are not captured in ASX filings or SEC insider trade databases. For a 30-plus-year pharmaceutical executive who has held C-suite positions at multiple companies, it is reasonable to assume meaningful private assets exist, but the size is genuinely unknown. This is the largest source of uncertainty in the estimate range.

Why different sites show different numbers

Net worth figures for executives like Ippolito vary widely across websites for a few concrete reasons, not just sloppy research.

• Data source differences: MarketScreener derives figures from insider trading filings and equity valuations tied to market prices on a specific date. A figure from April 2026 will differ from one calculated in January 2025 even if nothing changed in the underlying methodology, simply because Botanix's share price moved.
• Equity valuation assumptions: Some sites use the accounting value of unvested options and performance rights, which inflates the number relative to what is actually realizable today. Others use only disclosed realized proceeds, which understates it.
• Name conflation: Sites that aggregate social media data or scrape incomplete databases may mix the pharmaceutical executive with the Virginia Beach project manager, producing nonsense outputs.
• Update frequency: A site that published an estimate in 2022 and never revisited it will show a stale number that does not reflect compensation increases, share sales, or new equity grants.
• Methodology opacity: PeopleAI explicitly states its figures are based on 'social factors,' which is not a financial methodology at all. Numbers from such sources should be treated as illustrative at best.

How to verify and update the estimate yourself today

If you want to build the most current picture as of June 2026, here is exactly where to look and what to do with what you find.

1. Check the ASX announcements for Botanix Pharmaceuticals (ticker: BOT) at asx.com.au. Search for 'Vincent Peter Ippolito' or 'Ippolito' in the company's announcements to pull the most recent director change of interest notices. These will show current share and performance rights holdings.
2. Look up the current BOT share price and multiply it by the disclosed share holding to get a real-time equity value. This is the most dynamic part of the estimate.
3. Review Botanix's most recent annual report or prospectus for the updated remuneration table. The FY2025 figures cited here come from the most recent prospectus available as of this writing, but a new annual report will supersede them.
4. Search Benzinga's insider trades section for 'Vincent P Ippolito' to see whether any additional SEC-linked filings have appeared, which would indicate activity in US-listed securities.
5. Cross-check any aggregator site's number against the ASX filing date it would have used. If the site shows a number without a date or without linking to a specific filing, treat it with skepticism.
6. Accept that private wealth (real estate, personal investments, prior acquisition proceeds) cannot be verified from public data alone. Build your estimate as a range, not a point, and document where the uncertainty lives.

One thing worth noting: because Botanix is an ASX-listed company rather than a US-listed one, the primary disclosure trail runs through Australian exchange filings rather than SEC EDGAR. Many US-focused net worth aggregators miss this entirely, which explains why their figures for Ippolito are either absent or particularly unreliable compared to someone whose compensation appears in a US proxy statement.

The honest bottom line is that Vince Ippolito's net worth is verifiably meaningful given his compensation level and equity position, but the number is not knowable with precision from public data alone. The $5 million to $15 million range is defensible and grounded in real filings. Treat any site offering a single round number without source links as a guess, not a research output. For similar exercises involving other pharmaceutical and biotech executives, the same methodology applies: start with the company's disclosed remuneration, layer in insider filing data, and be explicit about what the private wealth gap means for your confidence interval.